Pharmacogenomics, defined
Pharmacogenomics (PGx) studies how inherited genetic differences can affect a person’s response to certain medicines. Testing can give your clinician another piece of information when considering a medication or dose.
Your care is more than a genetic result. Current medicines, medical history, kidney and liver function, and other factors matter too. Do not change medication without your clinician.
Read the clinical sourcesDiscuss your medicines and goals with your clinician. Confirm which test is useful, who orders it, the cost and coverage, and how the laboratory handles your sample and results.
Depending on the laboratory, collection may use cells from a cheek swab, saliva, or blood. Follow that laboratory’s preparation and collection instructions.
For some medicines, genetic variants help estimate metabolism—such as poor, intermediate, normal, rapid, or ultrarapid. Your clinician interprets the findings alongside your other medicines and health history.
Inherited variants generally stay the same, but test coverage and clinical guidance evolve. Keep a copy of your report and ask whether it needs reinterpretation or additional testing when your care changes.
Collection and interpretation: MedlinePlus. Your laboratory provides the instructions for your test.
For supported gene–drug pairs, results may help a clinician select a medicine or consider a different dose.
Some findings flag an increased chance of a specific adverse reaction. Testing cannot predict or prevent every side effect.
Bring your report into medication reviews. PGx can inform decisions, but it does not guarantee the right medicine on the first try or eliminate follow-up.
The evidence is specific to the gene, medicine, and clinical situation. A test panel is not a guarantee of better outcomes. Read the FDA’s explanation of the evidence and limitations.
Six areas of care from our community program. These are educational examples—not a recommendation to test everyone, a treatment plan, or a list of services available at every participating clinic.
Inherited variants can matter for the safety of some cancer medicines. Examples include DPYD with fluoropyrimidines and TPMT/NUDT15 with thiopurines. Tumor biomarker testing serves a different purpose: it looks at a cancer’s features to help identify treatment options.
Ask your clinician: Are we discussing inherited drug-response testing, tumor profiling, or both?
CYP2D6 affects the conversion of codeine and tramadol into active metabolites. Certain results can indicate reduced benefit or greater toxicity risk and may support a different prescribing choice. PGx does not measure pain or determine whether someone will develop an opioid use disorder.
Ask your clinician: Could a gene–drug interaction be relevant to a medicine in my pain-care plan?
CYP2C19 can affect how clopidogrel is activated. Some variants are associated with a lower antiplatelet response. Results may inform treatment in the appropriate clinical setting; they do not guarantee prevention of a heart attack, stroke, or bleeding.
Ask your clinician: Is there a guideline-supported PGx result that would change my treatment?
CYP2D6, CYP2C19, and CYP2B6 can affect the processing of certain antidepressants. Guidelines offer recommendations for selected gene–drug pairs, not every medicine or every gene on a commercial panel. Testing does not diagnose a mental health condition or guarantee a faster recovery.
Ask your clinician: Which parts of this report have evidence relevant to my current medicine?
Ask which, if any, drug-response tests are relevant to your specific urologic medicine. A medicine being processed by a particular enzyme does not, by itself, establish that testing improves care. In urologic cancers, tumor biomarker testing may guide selected therapies; it is not interchangeable with a general PGx panel.
Ask your clinician: Would a PGx test or a cancer-specific biomarker test answer the question we have?
Medication review can include treatment for co-occurring mental health conditions and pain. Evidence differs by medicine: CPIC does not recommend changing standard methadone prescribing on the basis of CYP2B6 genotype. A PGx report is not a measure of personal effort and cannot establish why a past treatment failed.
Ask your clinician: Could testing help with a specific medicine without interrupting my recovery treatment?
A conversation worth having
Start with your current care team or explore our Northeast Michigan provider directory. Current listings are not a complete specialist directory. Call to confirm services, appointments, ordering, and cost.
Educational content updated . This overview draws on the sources below; it is not individual medical advice or a substitute for clinical review. PGx Care does not order tests, interpret your results, or provide treatment.